Abstract
Clinical studies of WT1-targeted cancer vaccine are being performed. However, WT1-specific Th response in cancer patients remains unclear. Using quantitative real-time RT-PCR, we investigated IFN-γ and IL-10 mRNA expression from Th cells by stimulation with helper peptide WT1332. Seventeen patients, of whom 10 had achieved stable disease and the remaining 7 had progressive disease, were weekly vaccinated with WT1 CTL epitope (modified WT1235) and examined for WT1332-specific Th response. A clear correlation between WT1332-specific Th response and clinical response was observed at 4 weeks post-vaccination. In patients who responded, a clear inverse correlation between IL-10-type and IFN-γ-type WT1332-specific Th response was detected at pre- and 4 weeks post-vaccination, and the shift of the Th response from IL-10-type dominancy at early phase to IFN-γ-type dominancy at late phase was observed. From this study we concluded that occurrence of WT1332-specific Th response could predict good clinical response of WT1 CTL epitope vaccination.
Footnotes
-
Conflict of Interest Disclosure
All Authors have no financial conflicts of interest to disclose.
- Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved